What is inos.?

INO (Inovio Pharmaceuticals, Inc.) is a clinical-stage biotechnology company that develops DNA-based immunotherapies and vaccines. The company was founded in 1979 and its headquarters is located in Plymouth Meeting, Pennsylvania, United States. INO's proprietary platform technology, called SynCon, allows for the design and production of synthetic DNA sequences that can target specific diseases.

The company is primarily focused on developing immunotherapies and vaccines for infectious diseases, cancer, and other chronic diseases, including Alzheimer's and HIV. INO's lead product, VGX-3100, is a DNA-based immunotherapy for the treatment of human papillomavirus (HPV)-related precancerous lesions of the cervix and vulva.

INO has partnered with a number of organizations to advance its research and development programs, including the Bill and Melinda Gates Foundation, the National Institute of Allergy and Infectious Diseases (NIAID), and the Coalition for Epidemic Preparedness Innovations (CEPI).

INO is a public company and is listed on the NASDAQ stock exchange under the ticker symbol INO.